SG11201500134QA - Composition comprising a mixture of cd95-fc isoforms - Google Patents
Composition comprising a mixture of cd95-fc isoformsInfo
- Publication number
- SG11201500134QA SG11201500134QA SG11201500134QA SG11201500134QA SG11201500134QA SG 11201500134Q A SG11201500134Q A SG 11201500134QA SG 11201500134Q A SG11201500134Q A SG 11201500134QA SG 11201500134Q A SG11201500134Q A SG 11201500134QA SG 11201500134Q A SG11201500134Q A SG 11201500134QA
- Authority
- SG
- Singapore
- Prior art keywords
- isoforms
- mixture
- composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12176980 | 2012-07-18 | ||
| EP12176978 | 2012-07-18 | ||
| PCT/EP2013/065250 WO2014013039A1 (en) | 2012-07-18 | 2013-07-18 | Composition comprising a mixture of cd95-fc isoforms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201500134QA true SG11201500134QA (en) | 2015-03-30 |
Family
ID=48794121
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201500134QA SG11201500134QA (en) | 2012-07-18 | 2013-07-18 | Composition comprising a mixture of cd95-fc isoforms |
Country Status (18)
| Country | Link |
|---|---|
| US (5) | US9434783B2 (zh) |
| EP (4) | EP2875044B1 (zh) |
| JP (2) | JP6231562B2 (zh) |
| KR (1) | KR102201694B1 (zh) |
| CN (3) | CN109897115A (zh) |
| AU (2) | AU2013291984B2 (zh) |
| BR (1) | BR112015000732B1 (zh) |
| CA (2) | CA2878992C (zh) |
| DK (2) | DK2875045T3 (zh) |
| ES (2) | ES2674662T3 (zh) |
| HK (2) | HK1207095A1 (zh) |
| IL (1) | IL236659A (zh) |
| MX (1) | MX371430B (zh) |
| NZ (1) | NZ703546A (zh) |
| RU (2) | RU2648157C2 (zh) |
| SG (1) | SG11201500134QA (zh) |
| UA (1) | UA116889C2 (zh) |
| WO (2) | WO2014013037A1 (zh) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014013037A1 (en) * | 2012-07-18 | 2014-01-23 | Apogenix Gmbh | Shortened cd95-fc variants |
| AU2014261505B2 (en) * | 2013-04-29 | 2019-04-18 | Apogenix Ag | Method of diagnosing cancer |
| NO2776305T3 (zh) | 2014-04-23 | 2018-01-27 | ||
| WO2015165973A1 (en) | 2014-04-29 | 2015-11-05 | Apogenix Gmbh | Diagnostic anti-cd95l antibody |
| US9587215B2 (en) | 2014-08-07 | 2017-03-07 | General Electric Company | Devices, systems and methods for automated transfer of a sample |
| WO2016106291A1 (en) * | 2014-12-22 | 2016-06-30 | Alexion Pharmaceuticals, Inc. | Methods of purifying recombinant proteins |
| KR20220002336A (ko) | 2019-03-29 | 2022-01-06 | 미스트 쎄라퓨틱스, 엘엘씨 | T 세포 치료제를 제조하기 위한 생체외 방법 및 관련 조성물 및 방법 |
| IL293350A (en) | 2019-11-27 | 2022-07-01 | Myst Therapeutics Llc | A method for producing tumor-reactive t cells using modulatory substances |
| WO2021174208A1 (en) | 2020-02-27 | 2021-09-02 | Myst Therapeutics, Llc | Methods for ex vivo enrichment and expansion of tumor reactive t cells and related compositions thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE299936T1 (de) * | 1996-05-02 | 2005-08-15 | Mochida Pharm Co Ltd | Fas antigen-derivate |
| DE69730358T2 (de) * | 1996-10-31 | 2004-12-30 | Mochida Pharmaceutical Co. Ltd. | Fas-Antagonist FÜR DIE PROPHYLAXE ODER THERAPIE VON GVHD |
| ES2307313T3 (es) | 1997-02-27 | 2008-11-16 | Ono Pharmaceutical Co., Ltd. | Nuevos polipeptidos, adn que codifican y utilizan estos polpeptidos. |
| WO1999024069A1 (fr) * | 1997-11-10 | 1999-05-20 | Mochida Pharmaceutical Co., Ltd. | Medicaments preventifs et therapeutiques pour des affections pulmonaires diffuses |
| AU2002241922B2 (en) * | 2001-01-17 | 2007-10-25 | Aptevo Research And Development Llc | Binding domain-immunoglobulin fusion proteins |
| EP1273297A1 (en) * | 2001-07-06 | 2003-01-08 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Vitamin E for the treatment of diseases in which the binding of the transcription factor NF-KB and/or AP-1 to promoter target sites has a beneficial effect (eg AIDS, cardiac infarction) |
| CA2520254A1 (en) * | 2003-03-26 | 2004-10-07 | Apogenix Gmbh | Treatment of viral infections |
| US20100215637A1 (en) * | 2006-03-28 | 2010-08-26 | Biopharmica Ltd | Agent for the Treatment of Hormone-Dependent Disorders and Uses Thereof |
| AU2007263265A1 (en) * | 2006-06-21 | 2007-12-27 | Apogenix Gmbh | Differential IL-4 and/or IL-10 cytokine expression in human cancer |
| US9309320B2 (en) * | 2006-12-28 | 2016-04-12 | Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts | Neutralization of CD95 activity blocks invasion of glioblastoma cells in vivo |
| WO2008101671A2 (en) * | 2007-02-19 | 2008-08-28 | Apogenix Gmbh | Il-4 fc fusion proteins |
| EP2009022A1 (en) * | 2007-06-26 | 2008-12-31 | Apogenix GmbH | Trimeric death ligands with enhanced activity (tenascin) |
| EP2310409A2 (en) | 2008-06-17 | 2011-04-20 | Apogenix GmbH | Multimeric tnf receptors |
| JP5844158B2 (ja) * | 2009-01-09 | 2016-01-13 | アポゲニクス ゲゼルシャフト ミット ベシュレンクテル ハフツングＡｐｏｇｅｎｉｘ ＧｍｂＨ | 三量体形成融合タンパク質 |
| JP5754740B2 (ja) * | 2009-07-21 | 2015-07-29 | クイーン メアリー アンド ウェストフィールド カレッジＱｕｅｅｎ Ｍａｒｙ ａｎｄ Ｗｅｓｔｆｉｅｌｄ Ｃｏｌｌｅｇｅ | 細胞内薬物送達のためのｆａｓ（アポ−１，ｃｄ９５）標的化プラットフォーム |
| WO2011068993A1 (en) * | 2009-12-02 | 2011-06-09 | Acceleron Pharma Inc. | Compositions and methods for increasing serum half-life of fc fusion proteins. |
| WO2014013037A1 (en) * | 2012-07-18 | 2014-01-23 | Apogenix Gmbh | Shortened cd95-fc variants |
| AU2014261505B2 (en) * | 2013-04-29 | 2019-04-18 | Apogenix Ag | Method of diagnosing cancer |
-
2013
- 2013-07-18 WO PCT/EP2013/065248 patent/WO2014013037A1/en active Application Filing
- 2013-07-18 EP EP13737631.5A patent/EP2875044B1/en not_active Not-in-force
- 2013-07-18 BR BR112015000732-5A patent/BR112015000732B1/pt active IP Right Grant
- 2013-07-18 RU RU2015105328A patent/RU2648157C2/ru active
- 2013-07-18 RU RU2015105330A patent/RU2648146C2/ru active
- 2013-07-18 MX MX2015000731A patent/MX371430B/es active IP Right Grant
- 2013-07-18 AU AU2013291984A patent/AU2013291984B2/en active Active
- 2013-07-18 DK DK13742412.3T patent/DK2875045T3/en active
- 2013-07-18 EP EP13742412.3A patent/EP2875045B1/en active Active
- 2013-07-18 EP EP18164139.0A patent/EP3409686B1/en active Active
- 2013-07-18 KR KR1020157004183A patent/KR102201694B1/ko active IP Right Grant
- 2013-07-18 NZ NZ703546A patent/NZ703546A/en unknown
- 2013-07-18 AU AU2013291982A patent/AU2013291982B2/en not_active Ceased
- 2013-07-18 CN CN201910254827.8A patent/CN109897115A/zh active Pending
- 2013-07-18 WO PCT/EP2013/065250 patent/WO2014013039A1/en active Application Filing
- 2013-07-18 UA UAA201500254A patent/UA116889C2/uk unknown
- 2013-07-18 US US14/415,871 patent/US9434783B2/en active Active
- 2013-07-18 CN CN201380043661.6A patent/CN104640876A/zh active Pending
- 2013-07-18 EP EP18166228.9A patent/EP3406630B1/en active Active
- 2013-07-18 CA CA2878992A patent/CA2878992C/en active Active
- 2013-07-18 DK DK18164139.0T patent/DK3409686T3/da active
- 2013-07-18 CA CA2877989A patent/CA2877989C/en not_active Expired - Fee Related
- 2013-07-18 US US14/415,866 patent/US9315570B2/en active Active
- 2013-07-18 CN CN201380038208.6A patent/CN104662039B/zh not_active Expired - Fee Related
- 2013-07-18 JP JP2015522107A patent/JP6231562B2/ja active Active
- 2013-07-18 SG SG11201500134QA patent/SG11201500134QA/en unknown
- 2013-07-18 ES ES13742412.3T patent/ES2674662T3/es active Active
- 2013-07-18 ES ES18164139T patent/ES2924109T3/es active Active
- 2013-07-18 JP JP2015522106A patent/JP6317739B2/ja not_active Expired - Fee Related
-
2015
- 2015-01-11 IL IL236659A patent/IL236659A/en active IP Right Grant
- 2015-08-11 HK HK15107778.6A patent/HK1207095A1/zh unknown
- 2015-08-11 HK HK15107780.2A patent/HK1207096A1/zh not_active IP Right Cessation
-
2016
- 2016-04-18 US US15/131,219 patent/US9657083B2/en active Active
- 2016-08-17 US US15/239,127 patent/US9908928B2/en active Active
-
2018
- 2018-02-22 US US15/902,175 patent/US10370441B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1212701A1 (zh) | 恩雜魯胺製劑 | |
| HK1213798A1 (zh) | 治療性化合物和組合物 | |
| HK1210041A1 (zh) | 包含半氟化烷烴的混合物的組合物 | |
| EP2709972A4 (en) | NON-FLAMMABLE COMPOSITIONS OF CHLOROTRIFLUOROPROPENE | |
| EP2855550A4 (en) | POLYURETHANE COUPLING COMPOSITIONS | |
| HK1207095A1 (zh) | 包含 同種型的混合物的組合物 | |
| EP2917314A4 (en) | OLIGOMERATZUSAMMENSETZUNG | |
| HK1216503A1 (zh) | 用於經皮傳遞安非他命的組合物及方法 | |
| HK1210709A1 (zh) | 外用組合物 | |
| HK1216250A1 (zh) | '- '-羥基-二氫麥角胺化合物及組合物 | |
| GB201200707D0 (en) | Composition | |
| IL236312A0 (en) | Preparation of 18f-flucyclobin | |
| EP2769718A4 (en) | MEDICINAL COMPOSITION | |
| EP2878295A4 (en) | COMPOSITION | |
| EP2867199A4 (en) | STABLE COMPOSITIONS OF ESOTRERODINE | |
| GB201420971D0 (en) | Therapeutic composition | |
| ZA201402166B (en) | Compositions of efavirenz | |
| EP2837670A4 (en) | COMPOSITION CONTAINING FLUOROBIPHENYL | |
| IL217807A0 (en) | Therapeutic compositions | |
| HK1207558A1 (zh) | 丙炔基氨基茚滿透皮組合物 | |
| EP2938431A4 (en) | PREPARATION OF ALUMINUM OXIDE SILICATE COMPOSITION | |
| EP2910537A4 (en) | AGENT COMPOSITION GENERATING GAS | |
| EP2910538A4 (en) | AGENT COMPOSITION GENERATING GAS | |
| GB201218355D0 (en) | Surfacing mixture | |
| EP2702991A4 (en) | COMPOSITION OF ENTACOPONE |